Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration

Shaikh, Saad; Olson, John C.; Richmond, Preston P.

doi:10.4103/0301-4738.36489

Cited by 15 publications

(12 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several recent publications have reported RPE tears associated with the use of intravitreal anti-VEGFs in choroidal neovascularization associated with AMD. [72][73][74] The reported incidence of RPE tear after anti-VEGF therapy varies from 0.06 to 27% and seems to be higher than the incidence in the natural course of the disease. 75 Pre-existing RPE detachment (PED) or fibrovascular PED is considered the major risk factor for RPE tear.…”

Section: Adverse Events Following Intravitreal Anti-vegf Injections: mentioning

confidence: 99%

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

Falavarjani

Nguyen

2013

Eye

729

505

View full text Add to dashboard Cite

Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.

show abstract

Section: Adverse Events Following Intravitreal Anti-vegf Injections: mentioning

confidence: 99%

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

Falavarjani

Nguyen

2013

Eye

729

505

View full text Add to dashboard Cite

show abstract

“…The general consensus is that retinal pigment epithelium tear is the ocular side effect of intraocular antiangiogenic pharmacotherapy and is not related with any specific anti-VEGF drug [22][23][24] . The latest findings by Leon et al [25] evidenced that in 40% of AMD cases the RPE tears occurred within two years of anti-VEGF Shahsuvaryan ML.…”

Section: Retinal Pigment Epithelial Tearmentioning

confidence: 99%

Pharmacovigilance in Intraocular Antiangiogenic Therapy

Shahsuvaryan

2015

International Journal of Ophthalmic Research

View full text Add to dashboard Cite

pegaptanib sodium, ranibizumab, aflibercept. The articles of high or medium clinical relevance were selected for review. Results: Almost uniformly all trial evaluating ocular safety of antiangiogenic agents reveal the serious side effects including geographic atrophy, pigment epithelial tear, ocular hemorrhage despite the fact that the incidence is low. Ocular safety concern in intraocular pharmacotherapy by anti-angiogenic agents has a strong body of clinical evidence, resulting in plenty of peer reviewed clinical articles. Conclusion: Currently available findings obviate the need to raise awareness about chemical compound-related ocular side effects in patients with eye diseases treated by antiangiogenic agents. Hopefully that noninvasive therapeutic options will become available soon. INTRODUCTIONVascular endothelial growth factor (VEGF) plays an important role not only in the pathophysiology of several light-threatening retinal disorders such as age-related macular degeneration, retinal vein occlusion, diabetic macular edema and proliferative diabetic retinopathy contributing to increased permeability across both the blood-retinal and blood-brain barrier, but also in physiology of the eye [1] . ABSTRACTContext: Currently several antiangiogenic agents are being widely and successfully used for the treatment of eye diseases like neovascular macular degeneration, retinal vein occlusion and diabetic macular edema. The discovery of anti-VEGF (Vascular endothelial growth factor) agents has revolutionized the treatment of these conditions. Ophthalmology has witnessed an explosion in the number of intravitreal injections delivered to patients over the past 10 years, driven in large part by the introduction and rapid incorporation of therapy with anti-VEGF agents. Objective: Taking into consideration that VEGF plays an important role not only in the pathophysiology of several sight-threatening retinal disorders such as age-related macular degeneration, retinal vein occlusion, diabetic macular edema and proliferative diabetic retinopathy, but also in the physiology of the eye, and that more data are becoming available in intraocular antiangiogenic therapy, chemical compound-related ocular side effects across multiple antiangiogenic agents should be analyzed critically. Methods: A comprehensive literature search was conducted on Medline, PubMed, and Google Scholar databases in February 2015. Search temporal limits included articles published from 2005 to 2015 with the purpose of providing the most recent evidence. Studies were queried using the following keywords in various combinations: antiangiogenics in eye diseases, intravitreal pharmacotherapy by anti-VEGF, adverse effects, potential ocular hazards, bevacizumab,

show abstract

“…In letzter Zeit sind viele neue Verfahren und Medikamente entwickelt worden, die den Fortschritt der Makuladegeneration zu blockieren oder zu verlangsamen versuchen. Dazu zählen die photodynamische Therapie (PDT), die unter bestimmten Voraussetzungen zu einer Stabilisierung des Befundes führt [17,18,20], die Anti-VEGF-Therapie und die Gentherapie [26]. Die Anwendung dieser Therapieprinzipien in der Behandlung von der altersbedingten Makuladegeneration wurde zuerst durch klinische Versuche mit Pegaptanib-Natrium (Macugen, Eyetech/Pfizer) und später mit Ranibizumab (Lucentis, Genentech) eingeführt [11,17].…”

Section: Abstract !unclassified

Der Einfluss von Bevacizumab auf die Ultrastruktur choroidaler Neovaskularisationsmembranen bei Patienten mit altersbedingter Makuladegeneration

Vidinova¹,

Vidinov²

2009

Klin Monatsbl Augenheilkd

View full text Add to dashboard Cite

Our results indicate that intraviterally administered Avastin causes changes in the new vessel walls and in the extracellular matrix components. It diminishes the fenestration of the endothelial cells but also increases the risk of vessel occlusions and may have an alterating effect on the RPE cells. Although Avastin has the potential to improve the quality of life, patients subjected to the treatment should be carefully selected and constantly monitored.

show abstract

Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration

Cited by 15 publications

References 12 publications

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

Pharmacovigilance in Intraocular Antiangiogenic Therapy

Der Einfluss von Bevacizumab auf die Ultrastruktur choroidaler Neovaskularisationsmembranen bei Patienten mit altersbedingter Makuladegeneration

Contact Info

Product

Resources

About